CSL Limited (CSJ) - Total Liabilities
Based on the latest financial reports, CSL Limited (CSJ) has total liabilities worth €17.90 Billion EUR as of December 2024. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
CSL Limited - Total Liabilities Trend (2014–2025)
This chart illustrates how CSL Limited's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
CSL Limited Competitors by Total Liabilities
The table below lists competitors of CSL Limited ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
COMPASS GROUP
F:XGR
|
Germany | €18.14 Billion |
|
Great-West Lifeco Inc.
TO:GWO
|
Canada | CA$829.83 Billion |
|
IDEXX Laboratories Inc
NASDAQ:IDXX
|
USA | $1.75 Billion |
|
Occidental Petroleum Corporation
NYSE:OXY
|
USA | $46.71 Billion |
|
RIO Tinto Ltd
AU:RIO
|
Australia | AU$61.12 Billion |
|
Maruti Suzuki India Limited
NSE:MARUTI
|
India | Rs387.09 Billion |
|
Axis Bank Limited
NSE:AXISBANK
|
India | Rs16.01 Trillion |
|
Fannie Mae
LSE:0IL0
|
UK | $4.17 Trillion |
Liability Composition Analysis (2014–2025)
This chart breaks down CSL Limited's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.86 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.96 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.47 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how CSL Limited's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for CSL Limited (2014–2025)
The table below shows the annual total liabilities of CSL Limited from 2014 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-06-30 | €18.00 Billion | -3.35% |
| 2024-06-30 | €18.62 Billion | +1.16% |
| 2023-06-30 | €18.41 Billion | +33.70% |
| 2022-06-30 | €13.77 Billion | +40.85% |
| 2021-06-30 | €9.78 Billion | -24.93% |
| 2020-06-30 | €13.02 Billion | +29.30% |
| 2019-06-30 | €10.07 Billion | +11.19% |
| 2018-06-30 | €9.06 Billion | +16.92% |
| 2017-06-30 | €7.75 Billion | +15.16% |
| 2016-06-30 | €6.73 Billion | +84.10% |
| 2015-06-30 | €3.65 Billion | +17.28% |
| 2014-06-30 | €3.12 Billion | -- |
About CSL Limited
CSL Limited engages in the research, development, manufacture, market, and distribution of biopharmaceutical products and vaccines in Australia, the United States, Germany, the United Kingdom, Switzerland, China, Hong Kong, and internationally. The company operates through CSL Behring, CSL Seqirus, and CSL Vifor segments. The CSL Behring segment manufactures, markets, and distributes plasma produ… Read more